Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I relative bioavailability and food-effect study of BLZ945 granules vs capsules in healthy Japanese adults
jRCT2031230272Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotuletinib (3 arms), sponsored by Novartis. Primary endpoints: AUClast, AUCinf and 1 more. Started Oct 2023; status: completed.
02
Drugs
sotuletinib
Beyond the preview
Go deeper on jRCT2031230272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230272.